Saltar al contenido
Merck

F-017

Supelco

(±)-Flecainide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C17H20F6N2O3
Número de CAS:
Peso molecular:
414.34
Número CE:
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

grado

certified reference material

formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F

InChI

1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

Clave InChI

DJBNUMBKLMJRSA-UHFFFAOYSA-N

Información sobre el gen

human ... SCN5A(6331)

Descripción general

Flecainide, marketed under trade names such as Almarytm, Apocard, Ecrinal®, and Flécaine, is a class Ic antiarrhythmic drug used to prevent and treat a variety of cardiac arrhythmias. This Certified Spiking Solution® is suitable for use as a starting material in the preparation of calibrators, controls, or linearity standards in flecainide therapeutic drug monitoring methods by LC/MS or LC that ensure patients remain within the drug′s narrow therapeutic range.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Ecrinal is a registered trademark of Laboratoires Asepta Corporation Monaco
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 2

1 of 2

Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated
Lovely Chhabra et al.
Indian heart journal, 64(4), 404-407 (2012-08-30)
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in an elderly
[Flecainide intoxication].
Santiago Nogué et al.
Medicina clinica, 140(1), 46-46 (2012-10-03)
Heather Ellsworth et al.
Pacing and clinical electrophysiology : PACE, 36(3), e87-e89 (2012-08-14)
Flecainide is a Vaughan Williams Class Ic antidysrhythmic associated with PR, QRS, and QTc prolongation on the electrocardiogram and development of life-threatening cardiac toxicity in overdose. The cornerstone of treatment is fluid resuscitation and the administration of magnesium and sodium
Jens Cosedis Nielsen et al.
The New England journal of medicine, 367(17), 1587-1595 (2012-10-26)
There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation. We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico